Gerresheimer Faces Index Exclusion Amid Accounting Probe and Financial Strain

German pharma packaging firm Gerresheimer to be removed from SDAX after missing audit deadline due to BaFin probe, causing covenant breaches and major impairments.

The German pharmaceutical packaging specialist Gerresheimer is set for removal from the SDAX index. This decisive action by Deutsche Börse follows the company's failure to publish its audited financial statements for 2025 by the March 31, 2026, deadline. The delay stems from a complex audit and a deeper regulatory conflict over accounting standards, which is now significantly impacting the firm's financial operations.

Regulatory Scrutiny Halts Financial Reporting

At the core of the missed reporting deadline is an ongoing examination by the German financial regulator, BaFin. The investigation, focusing on the company's 2024 and 2025 fiscal years, involves auditors from Grant Thornton working alongside the regular auditor, KPMG. Authorities are scrutinizing the booking of revenues and costs related to specific "bill-and-hold" agreements, assessing potential non-compliance with International Financial Reporting Standards (IFRS). Compiling the necessary documentation for this probe has proven far more time-consuming than management initially anticipated.

Operational Fallout: Covenant Breaches and Asset Impairments

The absence of finalized accounts is creating substantial operational ripple effects. Gerresheimer has acknowledged that the delay constitutes a breach of its existing financial covenants, prompting ongoing discussions with its lenders. Concurrently, the company announced substantial non-cash impairment charges totaling between 220 and 240 million euros. These write-downs primarily relate to technology projects at its subsidiary Sensile Medical AG and the planned closure of the Moulded-Glass plant in Chicago Heights, scheduled for the end of 2026.

The formal ejection from the SDAX will compel institutional investors and index-tracking funds to divest their holdings. This technically driven selling pressure adds to the stock's existing woes. Over a twelve-month period, Gerresheimer shares have plummeted by more than 72 percent, currently trading at 20.78 euros. The dividend for the past fiscal year has already been reduced to the statutory minimum of 0.04 euros per share.

Revised Timeline Points to Summer Resolution

A formal resolution to the situation is not expected before early summer. The company's board now targets June 2026 for the publication of the audited annual report. This postponement also forces the delay of the quarterly figures originally scheduled for April 16 and the Annual General Meeting set for early June. Furthermore, the company's revenue guidance of 2.3 to 2.4 billion euros for the current year is now subject to significant reservation pending the conclusion of the BaFin procedures and negotiations with its banking partners.